Drug development platforms such as mRNA, CRISPR, and gene therapies combined with cost-effective development are creating spectacular economic opportunities.

New firms are targeting large markets including treatments for cancer, auto-immune disease, and other pathologies of the immune system, the brain, and infectious diseases.